Clinical trial
Patient Characteristics and Treatment Modalities in COPD Patients Assessed by GOLD2016 : a Cross-Sectional Study in China
NCT03161587 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Patient Characteristics and Treatment Modalities in COPD Patients Assessed by GOLD2016 : a Cross-Sectional Study in China
- Lead sponsor
- GlaxoSmithKline
- Phase
- Observational
- Overall status
- Completed
- Start date
- May 31, 2017
- Completion date
- December 31, 2018
- Enrollment
- 848 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.